Stock DNA
Pharmaceuticals & Biotechnology
SEK 26 Million ()
NA (Loss Making)
NA
0.00%
-1.46
0.00%
0.00
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-65.48%
0%
-65.48%
6 Months
-35.55%
0%
-35.55%
1 Year
-41.68%
0%
-41.68%
2 Years
-96.75%
0%
-96.75%
3 Years
-99.8%
0%
-99.8%
4 Years
-99.98%
0%
-99.98%
5 Years
-99.97%
0%
-99.97%
Qlife Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-69.20%
EBIT Growth (5y)
12.51%
EBIT to Interest (avg)
-19.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.99
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.80
EV to EBIT
-1.91
EV to EBITDA
-2.01
EV to Capital Employed
15.77
EV to Sales
40.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-826.92%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-4.90
-5.30
7.55%
Interest
0.00
0.50
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.20
-6.10
14.75%
Operating Profit Margin (Excl OI)
-50,163.50%
-50,790.90%
62.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 14.75% vs 14.08% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.20
-50.00%
Operating Profit (PBDIT) excl Other Income
-12.90
-70.30
81.65%
Interest
0.10
7.40
-98.65%
Exceptional Items
0.00
-79.60
100.00%
Consolidate Net Profit
-37.40
-160.00
76.62%
Operating Profit Margin (Excl OI)
-258,560.00%
-315,889.30%
5,732.93%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -50.00% vs -98.89% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 76.62% vs -71.86% in Dec 2023
About Qlife Holding AB 
Qlife Holding AB
Pharmaceuticals & Biotechnology
Qlife Holding AB is a medical device company, based in Sweden. The Company testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer. The Company is located in Helsingborg.
Company Coordinates 
Company Details
Hamntorget 3 , HELSINGBORG None : 252 21
Registrar Details






